高级检索
    王华姨, 高莉莉, 赵彤, 沈栋林. 单用rhGH、GnRHa及联合应用对青春期早发育特发性矮身材患儿的疗效观察[J]. 徐州医科大学学报, 2020, 40(9): 699-702. DOI: 10.3969/j.issn.2096-3882.2020.09.018
    引用本文: 王华姨, 高莉莉, 赵彤, 沈栋林. 单用rhGH、GnRHa及联合应用对青春期早发育特发性矮身材患儿的疗效观察[J]. 徐州医科大学学报, 2020, 40(9): 699-702. DOI: 10.3969/j.issn.2096-3882.2020.09.018
    The clinical study of rhGH and GnRHa alone and their combination in the treatment of idiopathic short stature children with early puberty[J]. Journal of Xuzhou Medical University, 2020, 40(9): 699-702. DOI: 10.3969/j.issn.2096-3882.2020.09.018
    Citation: The clinical study of rhGH and GnRHa alone and their combination in the treatment of idiopathic short stature children with early puberty[J]. Journal of Xuzhou Medical University, 2020, 40(9): 699-702. DOI: 10.3969/j.issn.2096-3882.2020.09.018

    单用rhGH、GnRHa及联合应用对青春期早发育特发性矮身材患儿的疗效观察

    The clinical study of rhGH and GnRHa alone and their combination in the treatment of idiopathic short stature children with early puberty

    • 摘要: 目的 分析单用重组人生长激素(rhGH)与促性腺激素释放激素类似物(GnRHa)及二者联合使用治疗青春期早发育特发性矮身材患儿的近期疗效与安全性.方法 选取2017年9月—2019年6月于徐州医科大学附属医院治疗的青春期早发育特发性矮身材患儿作为研究对象,共60例.依据治疗方案的不同将患儿分成3组:单用rhGH治疗组、单用GnRHa治疗组、rhGH联合GnRHa治疗组,每组20例.定期监测身高、预测终身高(PAH);监测空腹血糖水平、甲状腺功能、肝功能及血清胰岛素样生长因子1(IGF-1).结果 随访1年后,3组患儿身高、骨龄、PAH与治疗前比较,差异均有统计学意义(P<0.05).rhGH联合GnRHa治疗组患儿的生长速度和PAH高于单用rhGH治疗组和单用GnRHa治疗组,差异有统计学意义(P<0.05).3组患儿治疗后未见明显血糖异常、肝功能异常及甲状腺功能异常等不良反应(P>0.05).结论 rhGH与GnRHa联合治疗在提高生长速度、改善PAH方面的疗效优于单用rhGH或GnRHa治疗,治疗后无明显不良反应.

       

      Abstract: ob<x>jective To analyze the short-term efficacy and safety of recombinant human growth hormone (rhGH), gonadotropin-releasing hormone analogue (GnRHa) alone and their combination in the treatment of early puberty children with idiopathic short stature (ISS).Methods From September 2017 to June 2019, 60 children with idiopathic short stature were randomly divided into three groups: group A (recombinant human growth hormone rhGH), group B (GnRHa) and group C (recombinant human growth hormone combined with gonadotropin-releasing hormone analogue). They were followed up every three months and supervised Height, weight, predicted final height (PAH), IGF-1, LH, FSH, E2 or T, uterus, ovary or testicle size, fasting blood glucose, thyroid function, liver function and other indicators were measured. Bone age was measured once every six months.Results After 1 half year follow-up, the height, bone age and predicted final height of the three groups were significantly different from those before treatment (P < 0.05), and the growth rate of the combined treatment group was higher than that of the single treatment group (P < 0.05). There was no significant difference in blood glucose, thyroid function and liver enzyme between the three groups (P > 0.05).Conclusion After rhGH and GnRHa alone and combined treatment, the height of children increased significantly, the effect of combined treatment group was better than that of single treatment group, and there was no significant adverse reaction in three groups before and after treatment.

       

    /

    返回文章
    返回